Fig. 1: Treatment intervals at study timepoints.
Percentage of eyes by last treatment interval after anti-VEGF treatment initiation at month 12 (A) and at month 24 (B). Groups included ≤Q8W, >Q8W-<Q12W, ≥Q12W-<Q16W, ≥Q16W intervals.
Fig. 1: Treatment intervals at study timepoints. | Eye
